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RANKing c-Jun in osteoclast development
Steven L. Teitelbaum
Department of Pathology, Washington University School of Medicine, St. Louis, Missouri, USA.
Pathological bone loss always reflects enhanced net osteoclastic activity. Rec-
ognition and binding of the receptor activator of NF-κB (RANK) by RANK 
ligand (RANKL) is the key osteoclastogenic event, and the signaling cascades 
induced by this reaction therefore contain potential anti-osteoporosis thera-
peutic targets. A study reported in this issue of the JCI documents that a piv-
otal component of RANKL/RANK-mediated osteoclast recruitment involves 
sequential induction of the transcription factors c-Jun and nuclear factor of 
activated T cells 2 (see the related article beginning on page 475).
What is an osteoclast?
Osteoporosis always represents an imbal-
ance in favor of osteoclast-mediated bone 
resorption relative to the bone-forming 
capacity of osteoblasts. In some conditions 
of accelerated skeletal loss, such as Paget 
disease, osteoclasts are greatly enlarged, 
which enhances the individual cell’s 
resorptive activity. Most osteopenic disor-
ders, however, develop as a consequence 
of accelerated bone degradation due to 
increased osteoclast number. Thus, inhi-
bition of osteoclast formation by estrogen 
supplementation, or osteoclast function by 
bisphosphonate administration, has been 
the most effective means of arresting path-
ological bone loss. However, both forms of 
therapy are not without drawbacks, and new 
anti-resorptive targets are rapidly emerging. 
In this issue of the JCI, Ikeda et al. elegantly 
show that the JNK-1–activated c-Jun sig-
naling pathway is key to osteoclastic bone 
resorption (1). The authors find that mice 
bearing a dominant-negative osteoclast-spe-
cific c-Jun transgene have impaired osteo-
clastogenesis and, because of failed bone 
resorption, develop increased bone mass in 
the form of osteopetrosis. Importantly, the 
failure of dominant-negative c-Jun trans-
genic mice to generate osteoclasts is due to 
arrested activation and expression of mem-
bers of the nuclear factor of activated T cells 
(NFAT) family of transcription factors in 
osteoclast precursors.
The osteoclast is a huge cell whose phe-
notype is characterized by its capacity to 
attach to bone and polarize its resorptive 
machinery toward the cell’s interface with 
mineralized matrix (2). It is a terminally 
differentiated polykaryon whose multinu-
cleation is a manifestation of fusion rather 
than endomitosis, and it is the unique 
resorbing cell of the skeleton.
RANK ligand is key
Donald Walker, in the 1970s, performed 
the first meaningful experiments with 
osteopetrotic mice, which have, from 
that time forward, served as the essen-
tial resource for understanding how 
osteoclasts are born, resorb bone, and 
die. Using cross-circulation and mar-
row cell transplantation, Walker estab-
lished that the enigmatic polykaryon is 
of hematopoietic origin (3). A decade 
later, Suda’s group documented that the 
osteoclast can be generated, in vitro, from 
mononuclear members of the monocyte/
macrophage family, thus establishing their 
identity as osteoclast precursors (4). Curi-
ously, however, Suda was unable to gener-
ate osteoclasts unless their mononuclear 
progenitors were in physical contact with 
marrow-derived mesenchymal stromal 
cells, including osteoblasts. Discovery of 
the molecule expressed on the surface of 
stromal cells that mediates commitment 
of macrophages to the bone resorptive 
phenotype remained the principal enigma 
of osteoclast biology until 1998, when this 
key osteoclastogenic moiety was identified 
as receptor activator of NF-κB (RANK) 
ligand (RANKL) (5, 6). RANKL is a mem-
ber of the TNF superfamily whose crystal 
structure reveals unique components that 
enable it to activate its osteoclastogenic 
receptor, RANK, on osteoclast precur-
sors (7) (Figure 1). While other cytokines, 
particularly TNF-α, may be profoundly 
synergistic, only activated RANKL/RANK 
signaling suffices and is essential for 
osteoclast differentiation (8, 9).
The discovery of the osteoclastogenic 
capacity of RANKL enables generation of 
large numbers of essentially pure popu-
lations of bona fide osteoclasts in vitro, 
which in turn permits meaningful bio-
chemical and molecular definition of 
this cell. We now know that RANKL is a 
homotrimer (7), which not only promotes 
differentiation of osteoclast precursors but 
also activates the mature bone-degrading 
polykaryon (10). Thus, RANKL and RANK, 
as well as their intracellular signaling path-
way, are presently the most promising anti-
resorptive therapeutic targets.
The osteoclast needs  
TRAF6, Fos, and Jun
The importance of activator protein-1 
(AP-1) transcription factors, specifically 
dimers of the Fos and Jun families of 
proteins, in the osteoclastogenic process 
was first documented in the laboratory 
of Erwin Wagner, wherein c-Fos knockout 
mice were shown to be osteopetrotic due 
to a complete absence of osteoclasts (11). 
Consequently, the discovery of RANKL 
as the key osteoclastogenic cytokine 
prompted interest in the mechanisms by 
which RANK activation regulates AP-1 
transcription factors.
Just why RANKL is unique among TNF 
superfamily members in its capacity to 
induce osteoclast differentiation is still 
unresolved but probably involves its interac-
tion with TNF receptor–associated factor 6 
(TRAF6) (12, 13). Other RANKL-stimulated 
intracellular signaling molecules essential to 
the osteoclast phenotype include the p50/
p52 NF-κB subunits and the PI3K/AKT axis. 
Similarly, the MAPKs extracellular regulated 
kinases 1 and 2 and p38 are required for 
osteoclast differentiation or function.
Association of RANKL and TRAF6 acti-
vates all key events involving AP-1–medi-
ated transcription of osteoclast specific 
genes. Expression of the c-Fos gene in 393T 
cells requires TRAF 6, but whether the same 
holds true in osteoclasts is unresolved. On 
the other hand, c-Jun is clearly RANKL 
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activated via TRAF6 by a process involv-
ing JNK1 but not JNK2 (14). c-Jun is not 
the only member of its family to regulate 
osteoclastogenesis, as Jun-B–deficient mice 
also have arrested bone resorption (15).
When transcriptionally active, c-Jun asso-
ciates with members of the Fos family of 
transcription factors, a number of which 
— such as Fra-1, itself a c-Fos target — may 
substitute for c-Fos in the osteoclastogenic 
process (16). Although c-Jun also homodi-
merizes, the fact that c-Jun overexpression 
does not rescue the c-Fos–/– osteopetrotic 
phenotype indicates that c-Jun is neces-
sary, but not sufficient, to transactivate 
osteoclast specific genes.
NFAT and AP-1
In 2002 Takayanagi et al. identified NFAT2 
by genome-wide screening as the predomi-
nant gene activated in osteoclast precursors 
under the influence of RANKL and docu-
mented the transcription factor’s essen-
tial role in osteoclastogenesis (17). RANK 
occupancy mobilizes intracellular calcium, 
a requisite for calcineurin-mediated NFAT 
activation (Figure 1). Moreover, RANKL 
not only induces the transcription factor’s 
expression but facilitates its nuclear trans-
location, where NFAT binds to its DNA 
response element via a ternary complex 
with AP-1 proteins, including Fos/Jun, to 
transactivate target genes (18). Thus, it is 
not surprising, in retrospect, that RANKL-
induced osteoclastogenesis involves part-
nering of Fos/Jun with NFAT2. The fact 
that Ikeda et al. (1) found that expression of 
NFAT2 itself is NFAT1/Fos/Jun–dependent 
is in keeping with the presence of NFAT and 
AP-1 response elements in the NFAT2 pro-
moter (19). Reflecting its role as an essen-
tial RANKL-activated signaling molecule, 
NFAT2, when overexpressed in wild-type 
macrophages, prompts osteoclast differ-
entiation in the absence of the osteoclas-
togenic cytokine (17). RANKL-stimulated 
gene transcription is, therefore, a reflection 
of NFAT partnering with Fos/Jun.
Thus, Ikeda et al. (1) provide evidence of 
important components of RANK-mediated 
osteoclastogenesis specifically as it pertains 
to the AP-1 transcription complex. Clearly, 
TRAF6 is an essential player in RANKL-
mediated c-Jun and NFAT activation and, 
perhaps, c-Fos expression. NFAT/Fos/Jun 
is a critical osteoclastogenic complex, 
and deletion of any of the three arrests 
osteoclast formation. The pivotal role that 
Ikeda et al. document for c-Jun in osteoclast 
formation is in keeping with the fact that 
the anti–bone resorptive effects of estrogen 
are substantially mediated by c-Jun repres-
sion (20). Given that RANKL expression is 
also enhanced in estrogen-deficient women 
(21), RANKL → TRAF6 → MAPK kinase 7 
(MKK7) → JNK1 → Jun → NFAT signaling 
is likely pivotal to the pathogenesis of post-
menopausal osteoporosis, and inhibition 
of any of the components will theoretically 
arrest accelerated bone resorption (Figure 
1). The therapeutic challenge is how to spe-
cifically target these intracellular signaling 
molecules in osteoclasts.
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Figure 1
The AP-1/NFAT transcription complex mediates osteoclast precursor differentiation. Osteo-
clastogenesis is initiated by RANKL occupying RANK on the surface of osteoclast precursors. 
Subsequent recruitment of TRAF6 initiates the 3 depicted signaling cascades, in addition to 
other pathways not shown here. Phosphorylation (P) activates c-Jun in an MKK7/JNK-1–depen-
dent manner, and NFAT1 is activated by dephosphorylation via calcium-mediated induction 
of calcineurin. RANKL/RANK also induces c-Fos expression by an incompletely understood 
mechanism. NFAT1 partners with the AP-1 proteins of the Fos/Jun families to transactivate the 
NFAT2 gene, the product of which forms a similar ternary transcription complex on osteoclastic 
genes eventuating in appearance of the mature osteoclast phenotype.
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AMP-activated protein kinase:  
the guardian of cardiac energy status
D. Grahame Hardie
Division of Molecular Physiology, Faculty of Life Sciences, Wellcome Trust Biocentre, University of Dundee, Dundee, United Kingdom.
Several years ago it was proposed that the AMP-activated protein kinase 
cascade might protect cells against stresses that deplete cellular ATP. 
Young et al. have now directly tested this by studying the effects of isch-
emia and reperfusion in perfused hearts from mice expressing a domi-
nant-negative mutant that suppresses the kinase activity in cardiac muscle 
(see the related article beginning on page 495). Compared with control 
hearts, the mutant hearts showed clear evidence for increased necrotic 
damage and increased apoptosis. These findings may have implications 
for the treatment of ischemic heart disease.
AMP-activated protein kinase (AMPK) is 
the downstream component of a protein 
kinase cascade that is highly conserved 
in all eukaryotic cells (1). AMPK is acti-
vated by the rising cellular AMP that (due 
to the action of adenylate kinase) always 
accompanies a fall in the cellular ATP/
ADP ratio, and this activation is antag-
onized by high concentrations of ATP 
(Figure 1). Downstream targets and pro-
cesses regulated by the kinase are being 
identified on a regular basis (Figure 2). 
In general, AMPK switches off ATP-con-
suming processes such as biosynthetic 
pathways, while switching on catabolic 
processes that generate ATP, including 
cellular uptake of glucose (2) and fatty 
acids (3) and increased fatty acid oxida-
tion (4) in the heart.
The first evidence that AMPK was acti-
vated by metabolic stresses appeared 13 
years ago, when my group found that 
AMPK was activated by ATP depletion 
caused by incubation of isolated rat 
hepatocytes with high fructose (5), while 
Witters et al. (6) reported that it was acti-
vated by various metabolic poisons in 
hepatoma cells. We proposed at the time 
Nonstandard abbreviations used: 5-aminoimidazole-
4-carboxamide riboside monophosphate (ZMP); AMP-
activated protein kinase (AMPK).
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Figure 1
Role of AMPK in regulating energy balance at the single-cell level. The way in which the AMPK 
system controls the balance between ATP consumption (e.g., by biosynthesis, cell growth, or 
muscle contraction) and ATP production via catabolism is illustrated. If the rate of ATP con-
sumption exceeds its rate of production, ADP will tend to rise and be converted to AMP by the 
enzyme adenylate kinase. The rise in level of the activating ligand AMP, coupled with the fall in 
level of the inhibitory nucleotide ATP, activates AMPK, which then switches off ATP-consuming 
processes and switches on catabolism in an attempt to redress the balance.
Downloaded on June  9, 2013.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/22644
